Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: Inhibition of human coronary artery smooth muscle cell proliferation, but not migration

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 165-174

  Lavigne, Mark C ^a   Grimsby, Jessica L ^a   Eppihimer, Michael J ^a  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

cell signaling; drug eluting stent; everolimus; migration; proliferation; vascular smooth muscle

Indexed keywords

CYCLIN D; EVEROLIMUS; PROTEIN P70;

ANTIPROLIFERATIVE ACTIVITY; ANTIRESTENOTIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESTENOSIS; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; CORONARY VESSELS; CYCLIN D; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SMOOTH, VASCULAR; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 84857057602     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823a39c7     Document Type: Article

References (57)

1. World Health Organization. The Global Burden of Disease-2004 Update. Geneva: World Health Organization; 2008.
2. Cowan PA, Helzer KE. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrol Nurs J. 2000;27:623-625.
3. Saloustros E, Mavroudis D, Georgoulias A. Paclitaxel and docetaxel treatment in breast cancer. Expert Opin Pharmacother. 2008;9: 2603-2616.
4. Dirksen MT, Vink MA, Suttorp MJ, et al. Paclitaxel-eluting stent versus conventional stent; in myocardial infarction with ST-segment elevation (PASSION) investigators. EuroIntervention. 2008;4:64-70.
5. Martin JL, Ellis SG, Colombo A, et al. Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a baremetal stent into a single coronary artery. Am J Cardiol. 2009;103: 11-16.
6. Li JJ, Qin XW, Yang XC, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. Clin Chim Acta. 2008;396: 38-42.
7. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299-1304. (Pubitemid 47454687)
8. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667. (Pubitemid 9114288)
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995; 332:1004-1014.
10. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, et al. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004;3:1050-1056. (Pubitemid 40268664)
11. Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinase switching between life and death. Pharm Res. 2004;50:545-549. (Pubitemid 39388965)
12. Jongkyeong C, Kuo CJ, Crabtree GR, et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69:1227-1236.
13. Carrera AC. TOR signaling in mammals. J Cell Sci. 2004;117: 4615-4616. (Pubitemid 39433427)
14. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative. Transplantation. 1997;64:36-42.
15. Patel JK, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother. 2006;7:1347-1355.
16. Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Cath Cardiovasc Interv. 2006; 68:97-103. (Pubitemid 44024469)
17. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the Pooled FUTURE I and II Trials). Am J Cardiol. 2006;98:464-469. (Pubitemid 44177577)
18. Ferri N, Granata A, Pirola C, et al. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol. 2008;74:144-153. (Pubitemid 351877002)
19. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1992;86:723-729.
20. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological and immunohistochemical analysis. Circulation. 1998;98:224-233. (Pubitemid 28337613)
21. Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to rituximab. Br J Haematol. 2006;134:4475-4484.
22. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther. 2003;2:222-232.
23. Parry TJ, Brosius R, Thyagarajan R, et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol. 2005;524:19-29. (Pubitemid 41606808)
24. Wessely R, Blaich B, Belaiba RS, et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Thromb Haemost. 2007;97:1003-1012. (Pubitemid 46939215)
25. Blagosklonny MV, Demidenko ZN, Giovino M, et al. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest. Cell Cycle. 2006;5:1574-1579. (Pubitemid 44091979)
26. Woods CM, Zhu J, McQueney PA, et al. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995;1:506-526.
27. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 1991;52:35-84.
28. Li PF, Dietz R, von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett. 1997;404:249-252. (Pubitemid 27113462)
29. Beyar R, Keren G, Leon MB, et al. Stent design and the biologic response. In: Garasic J, Rogers C, Edelman ER, eds. Frontiers in Interventional Cardiology. London: Marin Dunitz Ltd.; 1997:95-100.
30. Hughes AD, Clunn GF, Refson J, et al. Platelet-derived growth factor (PDGF): actions and mechanism in vascular smooth muscle. Gen Pharmacol. 1996;27:1079-1089. (Pubitemid 26375419)
31. Braun-Dullaeus RC, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001;21:1152-1158. (Pubitemid 34215143)
32. Polyak K, Lee M-H, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59-66.
33. Reynisdottir I, Polyak K, Iavaronne A, et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-b. Genes Dev. 1995;9:1831-1845.
34. Perkins LEL, Boeke-Purkis KH, Wang Q, et al. XIENCE Vtrade mark; everolimus- eluting coronary stent system: a preclinical assessment. J Interven Cardiol. 2009;22:S28-S40.
35. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Del Rev. 2006;58: 412-436. (Pubitemid 43949060)
36. Chong PH, Cheng JWM. Early experiences and clinical implications of drug-eluting stents: part 1. Ann Pharmacother. 2004;38:661-669. (Pubitemid 38352232)
37. Kibos A, Campeanu A, Tintoiu I. Pathophysiology of coronary artery in-stent restenosis. Acute Cardiac Care. 2007;9:111-119. (Pubitemid 46955240)
38. Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Del Rev. 2006;58:358-376. (Pubitemid 43816739)
39. Welt GP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-1776. (Pubitemid 35315761)
40. Sundberg LJ, Galante LM, Bill HM, et al. An endogenous inhibitor of focal adhesion kinase blocks Rac/JNK but not Ras/ERK-dependent signaling in vascular smooth muscle cells. J Biol Chem. 2003;278: 29783-29791. (Pubitemid 36962365)
41. Moss SC, Lightell DJ Jr, Marx SO, et al. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010;285:11991-11997.
42. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22: 159-168.
43. Zeng Z, Sarbassov DD, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007; 109:3509-3512. (Pubitemid 46572543)
44. Martin KA, Rzucidlo EM, Merenick BL, et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol. 2004;286:C507-C517. (Pubitemid 38292656)
45. Lavigne MC, Queen J, Kunkel E, et al. Biological profiling of drugs for treatment of in-stent restenosis. FASEB J. 2008;22:1148.1.
46. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008; 52:333-342. (Pubitemid 352001347)
47. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15: 1612-1622.
48. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99: 2164-2170. (Pubitemid 29196802)
49. Matter CM, Rozenberg I, Jaschko A, et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2006;48:286-292. (Pubitemid 46066833)
50. Schubert D, Harris AJ, Devine CE, et al. Characterization of a unique muscle cell line. J Cell Biol. 1974;61:398-413.
51. Luo Y, Marx SO, Kiyokawa H, et al. Rapamycin resistance tied to defective regulation of p27kip1. Mol Cell Biol. 1996;16:6744-6751. (Pubitemid 26389733)
52. Castagnino P, Kothapalli D, Hawthorne EA, et al. Cell-type- and cellcycle- specific anti-mitogenesis by cicaprost. Prostaglandins Other Lipid Mediat. 2010;93:20-24.
53. Roque M, Reis ED, Cordon-Cardo C, et al. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest. 2001;81:895-903. (Pubitemid 32553410)
54. Sakakibara K, Liu B, Hollenbeck S, et al. Rapamycin inhibits fibronectin- induced migration of the human arterial smooth muscle cell line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol. 2005;288:H2861-H2868. (Pubitemid 40720668)
55. Sun J, Marx SO, Chen H-J, et al. Role for p27kip1 in vascular smooth muscle cell migration. Circulation. 2001;103:2967-2972. (Pubitemid 32578136)
56. Rosner D, McCarthy N, Bennett M. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res. 2005;66:601-610. (Pubitemid 40725772)
57. Lavigne et al J Cardiovasc Pharmacol Volume 59, Number 2, February 2012 174